CHRU of NANCY
Vandœuvre-lès-Nancy, 54511, France
NCT Number: NCT06472440
: The evaluation of gliomas in imaging represents a real challenge today, at the initial diagnosis, for therapeutic planning or follow-up treatment of these lesions. There is an urgent need for non-invasive imaging tools to evaluate a glioma throughout its management. At present, the diagnosis of certainty is only obtained through an anatomo-pathological analysis with sampling during an invasive procedure (surgery or biopsy). Magnetic resonance imaging, through perfusion, diffusion imaging or spectroscopy is developing in gliomas. However, it remains time-consuming and is not always available. At the same time, positron emission tomography (PET) with amino acids is an interesting alternative for these brain tumours. Amino acid PET has the advantage of being more specific than the abnormalities detected in MRI and the amino acid radiotracers cross the blood-brain barrier, even if not broken, unlike Gadolinium in MRI. Among these radiotracers, 18F-FDOPA can, among other things, assist in the non-invasive staging of gliomas at initial diagnosis
Looking for future studies?
Notify Me18 year–95 year
All sexes
Observational
Vandœuvre-lès-Nancy, 54511, France
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Person who received full information on the organization of the research and who objected to the use of the data
Time frame: Day 1
Accuracy of the method
Time frame: Day 1
Sensibility of the method
Time frame: Day 1
specificity of the method
Central Hospital, Nancy, France
Other
Evaluation of the Use of a Method "Radiomics" for Positons Emission Tomography With Fluor-18-Fluoro-DOPA PET in Gliomas
Acronym: RADDOPAG-2
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03030066
Glioma, Neoplasms
Tokyo, Japan
View Trial DetailsNCT06368310
Brain Diseases, Brain Neoplasms
Salford, Greater Manchester, United Kingdom
View Trial DetailsNCT07673666
Astrocytoma, Astrocytoma of Brain
Mumbai, India
View Trial DetailsNCT07673679
Astrocytoma, Astrocytoma, Grade IV
Mumbai, India
View Trial Details